We orchestrate the immune system to target oncogenic driver mutations to deliver transformative therapies intended to cure patients.
Affini-T’s co-founders have proven expertise in innovation for immune cell therapies, and our experienced management team is committed to advancing breakthrough therapies for patients. Our validated TCR discovery platform leverages synthetic biology and gene editing technologies, allowing our ...
We orchestrate the immune system to target oncogenic driver mutations to deliver transformative therapies intended to cure patients.
Affini-T’s co-founders have proven expertise in innovation for immune cell therapies, and our experienced management team is committed to advancing breakthrough therapies for patients. Our validated TCR discovery platform leverages synthetic biology and gene editing technologies, allowing our team to overcome key hurdles in cellular engineering that have prevented the field from developing therapies for solid tumor cancers in the past.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.